Abstract: Little controlled drug administration data are available to aid in the interpretation of gamma-hydroxybutyric acid (GHB) distribution in conventional and nonconventional fluids and the potential correlation between the pharmacokinetics of GHB and drug effects. Single oral sodium GHB doses of 50 mg/kg were administered to five volunteers. Plasma, oral fluid, urine, and sweat were analyzed for GHB by gas chromatography-mass spectrometry. GHB stability in plasma was studied at different storage temperatures. Subjective effects were measured using a set of 13 different visual analog scales. Mean peak GHB plasma concentrations at 30 minutes were 83.1 mg/mL. After the absorption phase, concentrations declined to mean values of 0.9 mg/mL at 6 hours. GHB was found in oral fluid at peak value concentrations equivalent to one third to one fourth of those found in plasma. The oral fluid-to-plasma ratio varied two fold in the 1-to 6-hour time range but always was lower than unit. The mean half-life (t 1/2 ) of GHB was approximately 0.7 hour in plasma and approximately 1.2 hours in oral fluid. GHB urinary excretion is less than 2% of the dose administered. GHB was also detected in sweat at low concentrations. GHB showed a mixed sedative-stimulant pattern with subjective effects peaking between 1 and 1.5 hours after drug administration and lasting for 2 hours. Oral fluid and sweat appeared not to be suitable biologic matrices for monitoring GHB consumption. GHB -mediated subjective effects are related to GHB plasma concentrations.
INTRODUCTION
Gamma-hydroxybutyric acid (GHB, ''liquid ecstasy,'' gamma-hydroxybutyrate, 4-hydroxybutiric acid, 4-hydroxybutanoic acid, oxybate) is a short chain fatty acid. It is an endogenous metabolite and a precursor of the neurotransmitter gamma-aminobutyric acid. GHB can be formed in human peripheral tissues from two precursors, gamma-butyrolactone and 1,4-butanediol ( Fig. 1) and acts in the central nervous system as a neuromodulator. 1 GHB is marketed in the United States under the name Xyrem for the treatment of cataplexy in patients with narcolepsy and in some European countries as an anesthetic agent and for the treatment of alcohol withdrawal (eg, Alcover in Italy). GHB has also emerged as a major recreational drug and health problem all over the world. By the late 1990s, GHB had become a popular drug used in clubs and gained significant notoriety as a major drug of abuse and as a date rape drug. Gamma-butyrolactone and 1,4-butanediol, both GHB metabolic precursors, have also been abused in humans. During the last years, it has become a major concern in emergency departments of some countries as a result of an important increase in the number of cases of intoxication. GHB overdose frequently results in nonreactive coma associated with bradycardia, hypothermia, agitated delirium, myoclonus, and rarely seizure-like activity. 2 Although GHB has been successfully detected in urine and blood of consumers, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] drug measurement in biologic fluids to assess both voluntary and involuntary consumption has some drawbacks. First, GHB is eliminated from the body rapidly, making identification dependent on the time elapsed between consumption and biologic matrix collection. This fact addressed investigations toward the use of biologic matrices with time windows for drug detection wider than blood and urine such as hair. 13, 14 Second, a compounding difficulty resides in the fact that GHB is an endogenous compound present in the human body with measurable baseline concentrations both in blood and urine. [15] [16] [17] [18] Hence, different authors proposed cutoff (ie, 10 mg/mL for urine samples) concentrations to identify exogenous GHB exposure.
Finally, several studies underlined that endogenous GHB concentrations can be elevated both in antemortem and postmortem biologic samples resulting from storage conditions and enzymes responsible for biotransformation of GHB into the body (Fig. 1) . 15, 19, [20] [21] [22] [23] Whereas the possible influence of storage conditions and microorganisms in the production of GHB in postmortem specimens has been clarified, 22 ,24 data on GHB stability in stored biologic fluids from administration studies and intoxication cases are scarce.
Although several studies have addressed the measurement of GHB in plasma and oral fluid after single and repeated administrations, 3, 4, [25] [26] [27] there remain many questions on disposition of GHB biologic fluids other than plasma and urine, on the stability of the compound in stored biologic samples, and on the subjective effects induced by this drug in the range of doses commonly abused. In addition, few studies addressed the correlation of drug effects and concentrations in biologic fluids, including alternative matrices.
The aims of this study were as follows: 1) to investigate the presence and the time course of GHB in plasma, urine, oral fluid, and sweat after single oral administration; 2) to evaluate the stability of GHB in plasma under different storage conditions; and 3) to explore the potential correlation between the pharmacokinetics of GHB in different biologic matrices and some subjective effects.
MATERIALS AND METHODS

Human Subjects
Five male subjects were recruited by ''word of mouth'' and included in the study. Eligibility criteria required the recreational use of GHB on at least five occasions. Exclusion criteria included daily consumption of more than 20 cigarettes and more than 30 g of ethanol (3 units per day). All subjects gave their written informed consent before inclusion and were economically compensated for inconveniences caused by their participation in the study. 
Study Design
Subjects participated as outpatients in a 6 hour study session in which they were given a single dose of 50 (equivalent to 41.4 mg/kg of GHB) mg/kg of sodium GHB by the oral route. Participants were requested to abstain from consumption of any drug of abuse during the study period and urine drug testing (applying the cutoff values in parentheses) was performed before each study session for cannabinoids (50 ng/mL), cocaine (300 ng/mL), opiates (2000 ng/mL), amphetamine/ methamphetamine (1000 ng/mL), MDMA (500 ng/mL), barbiturates (200 ng/mL), benzodiazepines (300 ng/mL), and phencyclidine (25 ng/mL) (Instant-View; Alfa Scientific Designs, Poway, CA). For all groups of substances, participants tested negative before each experimental session. Subjects arrived at the laboratory at 8 AM after an overnight fast and had an indwelling intravenous catheter inserted into a subcutaneous vein in the forearm of the nondominant arm. Thereafter, they remained seated in a quiet room throughout the session. GHB (Alcover OS sodium GHB, 17.5% syrup; CT Laboratorio Farmaceutico, SRL, San Remo, Italiy) was orally administered around 9:00 AM in a fasting state. The dose (corresponding to appropriate milliliters of syrup) was diluted to 250 mL of a soda orange-based drink. Participants were told to drink the beverage as soon as possible (mean, 12 seconds; range, 5-20 seconds).
Collection of Blood, Oral Fluid, Urine, and Sweat Samples
Blood was collected at 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5 and 6 hr after GHB administration in heparinized tubes and immediately centrifuged. Samples of oral fluid were collected without any stimulation over a 1 min period at 0, 0.5, 1, 1.5, 2, 3, 4, 5 and 6 hr after drug administration. Immediately after drug administration, mouth was washed (100 mL of water) to minimize oral fluid contamination. Urine samples were collected before and at 0-3 and 3-6 hours after drug administration. Sweat samples were obtained by wiping the forehead with cotton fleece at 0, 0.5, 1, 2, 3, 4, 5, and 6 hours after drug administration. Additionally, a sweat patch (PharmChem Laboratories, Menlo Park, CA) was applied to the back of each participant after the skin was cleaned with a 70% isopropyl alcohol swab and removed 6 hours after administration. All biologic specimens were frozen at -20°C until analysis. No preservatives were added to the specimens.
Pharmacologic Effects
In the context of a dose-finding study for the performance of clinical trials intended at evaluating the pharmacology of GHB in humans, a number of physiological and subjective effects as well as psychomotor performance of subjects under the effects of the drug were measured. Results have been reported elsewhere. 28 In this article, some representative subjective effects induced by GHB are included to explore the potential correlation between its pharmacokinetics in different biologic matrices and drug effects.
Subjective effects were measured using a set of 13 different visual analog scales (VAS) of 100 mm labeled with different adjectives marked at opposite ends with ''not at all'' and ''extremely'' were used. Subjects were asked to rate effects of ''stimulated,'' ''high,'' ''any effect,'' ''good effects,'' ''bad effects,'' ''liking,'' ''content,'' ''drunkenness,'' ''drowsiness,'' ''dizziness,'' ''confusion,'' ''depression or sadness,'' and ''relax.'' Scales were administered at -15 minutes (immediately before drug administration), 0.25, 0.50, 0.75, 1, 1.50, 2, 3, 4, 5, and 6 hours after GHB administration.
Chemicals
Pure standards of GHB sodium salt and N,O-Bis(trimethylsilyl) trifluoroacetamide with 1% trimethylchlorosilane (BSTFA-1% TMCS) were obtained from Sigma Chemicals (St. Louis, MO). GHB-d 6 methanolic solution (1 mg/mL) was purchased from Cerilliant (Austin, TX). Ultrapure water and all other reagents of analytic grade were from Carlo Erba (Milano, Italy).
Determination of Gamma-Hydroxybutyric Acid Concentrations in Biologic Fluids
Frozen oral fluid, plasma, and urine samples were allowed to thaw at room temperature. Before analysis, oral fluid was centrifuged to discard the mucous part, which accumulated at the bottom. Aliquots of 100 mL plasma, oral fluid, and urine were added with 5 mg of GHB-d 6 (as internal standard, 5 mL of the 1 mg/mL methanolic solution) and 200 mL of acetonitrile. After 30 second vortex and 5 minute centrifugation at 1000g, 150 mL of the supernatant was transferred to a clean extraction tube and evaporated to dryness under a nitrogen steam (40°C, 10 minutes). The dried extracts were derivatized with 50 mL of BSTFA-1% TMCS for 30 minutes at 70°C. For GHB determination in sweat, the cotton wipe or the sweat patch spiked with 5 mg of GHB-d 6 was extracted with 5 mL of acetonitrile (covering the whole cotton fleece or the patch). The acetonitrile extract was evaporated to dryness and derivatized as described previously.
A 1 mL aliquot of derivatized samples was injected onto a Hewlett-Packard 6890 gas chromatograph coupled to a Hewlett-Packard P5973 quadrupole mass spectrometer (Agilent, Palo Alto, CA). The capillary column was a crosslinked 5% phenyl-methylsilicone (12 m 3 0.2 mm internal diameter and 0.33 mm film thickness, Ultra-2; Agilent). The samples were injected in splitless mode and helium gas was used as carrier at a flow rate of 1.2 mL/minute (measured at 180°C). The injector and detector temperatures were both maintained at 280°C, respectively. The temperature program was initially set at 60°C for 2 minutes and increased to 180°C at 20°C/minute, then 35°C to 250°C, and then held for 4 minutes. The total run time was 14 minutes. The mass spectrometer was operated in the electron ionization and selected ion monitoring acquisition mode. The following ions were monitored (underlined ions were used for quantification): GHB-bis-TMS: m/z 233, 204, 117; GHB-d 6 -bis-TMS: m/z 239.
Before application to real samples, the analytical method was tested for plasma, oral fluid, and urine after a 4 day validation protocol. Linearity, precision, accuracy, stability (freeze/thaw cycles), limits of detection, and quantification were assessed.
Calibration standards containing 1, 25, 50, 100, 200, 300 mg/mL of GHB were prepared in duplicate daily for each analytic batch by adding suitable amounts of methanol working solutions (10 mg/mL, 100 mg/mL, 1 mg/mL) to glass tubes and evaporated to dryness (40°C, 3 minutes). Residue was reconstituted with 100 mL of prechecked drug-free (see further in this section) oral fluid, plasma, and urine samples. Quality control (QC) samples of 5 (low control), 100 (medium control), and 200 mg/mL (high control) GHB in plasma, oral fluid, and urine were prepared, distributed in aliquots, and stored at 220°C. QC samples were included in each analytic batch to check the daily quality of the analytic process.
Peak area ratios between GHB and internal standard were used for calculations using a weighted (1/concentration) least square regression analysis. Standard deviation of the analytic background response was used to estimate the lower limit of quantification (LLOQ = 10 standard deviations) and the limit of detection (LOD = 3 standard deviations). Because GHB is an endogenous compound, a number of replicates (n = 8) of different biologic matrices (plasma, oral fluid, and urine) under basal conditions from subjects participating in the clinical studies as well as those used for the preparation of calibrators were analyzed by isotopic dilution mass spectrometry using the deuterated analog of GHB at the concentration of 0.25 mg/mL and aliquots of 200 mL of the corresponding matrix. The purpose of this approach was to check that basal GHB endogenous concentrations were well below the LLOQ of the analytic method.
Extraction recoveries were calculated by comparing the peak areas of four replicates of QC samples after the previously mentioned extraction procedure with matched methanolic dilutions of GHB and IS.
Nine replicates of the three QC samples were analyzed for the determination of intraday precision and accuracy, whereas the interday precision and accuracy were determined for three different assays of three replicates of the previously mentioned QC samples. Precision was expressed as the relative standard deviation of concentrations calculated for QC samples. Accuracy was expressed as the relative error of the calculated concentrations. Interday precision has been estimated through analysis of variance of determinations in three consecutive days estimating components of precision with the formula given in Krouwer and Rabinowitz. 29 The effects of three freeze-thaw cycles (storage at -20°C) on the compound stability in different biologic fluids were evaluated by repeated analysis (n = 3) of QC samples. The stability was expressed as a percentage of the initial concentration of the analyte spiked in different matrices and quantified just after preparation.
Effect of Storage Temperature
Plasma samples were distributed in aliquots and stored at different temperatures [room temperature (25°C), refrigerated (4°C), frozen (220°C), and heated (37°C)]. The storage subsets were analyzed in triplicate at 1, 5, 24, and 48 hours after preparation and compared with a triplicate immediately analyzed. Differences from the initial concentration higher than the precision of the method were considered relevant.
Pharmacokinetics Parameters
The following parameters were determined: with regard to plasma and oral fluid concentrations of GHB, peak concentration (C max ), time to reach peak concentrations (t max ), area under the concentration-time curve from 0 to 6 h (AUC 0-6 ), elimination half-life (t 1/2 ), and elimination constant (Ke). AUCs were calculated by the linear trapezoidal rule.
Pharmacokinetic parameters were obtained with use of specific functions of a computer program (PK Functions for Microsoft Excel; Microsoft Corp., Redmond, WA).
RESULTS
Method Validation
Calibration curves were linear over the concentration range 0.2 (LLOQ) to 300 mg/mL GHB in the case of plasma, oral fluid, and urine samples and determination coefficients, r 2 , for all the calibration curves were always greater than 0.990.
Mean extraction efficiency of GHB was always greater than 95% in all biologic fluids under investigation. Table 1 shows the results obtained for intraday and interday precision and accuracy calculations for GHB in biologic matrices under examination. These results satisfactorily met the internationally established acceptance criteria. 30, 31 No relevant degradation was observed after any of the three freeze-thaw cycles with differences in the initial concentration lower than 10%.
Effect of Storage Temperature in Gammahydroxybutyric Acid Plasma Concentrations
GHB was stable at all temperatures tested. A higher variability in GHB plasma concentrations was mainly observed at 25°C and 37°C; nevertheless, changes were never higher than the precision of the analytic method.
Concentration-time Profiles and Pharmacokinetics of GHB in Plasma and Oral Fluid Samples
Mean concentration-time curves of GHB in plasma and oral fluid after 50 mg/kg of sodium GHB are presented in Figure 2 .
GHB was detected in all baseline plasma samples with mean estimated concentrations of 0.04 6 0.01 mg/mL. GHB was readily absorbed after oral administration and rapidly eliminated (t max and t 1/2 , 1 hour). After drug administration, concentrations peaked between 30 and 60 minutes after drug administration (C max range, 51.0-123.5 mg/mL) ( Table 2) . After the absorption phase, concentrations declined to a mean values at 6 hours of 0.9 mg/mL.
GHB was detected in all baseline oral fluid samples with mean estimated concentrations of 0.12 6 0.02 mg/mL. The time course of drug concentration in oral fluid was similar to that seen in plasma with maximum concentrations achieved at 0.5 hour (C max range, 11.6-49.0 mg/mL); then concentrations decreased to mean values of 0.5 mg/mL at 6 hours.
Oral fluid GHB mean concentrations time course paralleled those found in plasma. However, individual values for oral fluid and plasma did not correlate. The oral fluid to plasma ratio (S/P ratio) after drug administration was lower than unit at all times tested (Fig. 3) and ranged between 0.5 and 0.2. A high interindividual variability in S/P ratio was observed among subjects.
Excretion of Gamma-Hydroxybutyric Acid in Urine
A summary of GHB urinary excretion is shown in Table 3 . GHB was detected in urine at baseline samples with estimated concentrations of 0.21 6 0.14 mg/mL. The highest GHB recovery was found in the 0-to 3-hour urine samples. Concentrations of GHB in urine (median and percentiles 25/75) for the two collection periods evaluated (0-3 hours and 3-6 hours) were, respectively, 584.0 (435.8-763.0) and 60.5 (12.8-107.5) mg/mL. Less than 2% of the dose tested was recovered in urine for the 0-to 6-hour collection period.
Excretion of Gamma-Hydroxybutyric Acid in Sweat
Sweat samples were analyzed following an analytic approach similar to the one applied for other fluids evaluated in the present report. A preliminary study for the cotton wipe collection of blank samples made in 20 drug-free male healthy volunteers showed a very high variability in GHB endogenous basal concentrations. There was a more than a 100 fold intersubject difference in sweat GHB values. The range of concentrations were 0.03 to 5.46 mg per wipe. Tentatively, these differences were attributed to the fact that those subjects, displaying higher concentrations, presented acne and oily skin. This was an empiric and plausible observation that should be verified experimentally in further studies. Proper validation of GHB in sweat was not possible as a result of the inability to find a representative blank sample for preparation of calibrators and controls.
A preliminary assessment of baseline amounts of GHB measured in cotton wipes swabbed for 10 seconds on the armpit and forehead of subjects participating in the study showed high variability. This observation was biased by a subject with basal sweat GHB concentrations of 3.6 mg per wipe. Concentrations measured overtime never increased more than 1 to 2 mg per wipe over basal values. GHB was also found in the sweat patches (0-to 6-hour accumulation) in amounts ranging between 0.9 mg and 1.3 mg.
Pharmacologic Effects
Subjective effects corresponding to VAS ''stimulated'' and ''drowsiness'' are presented in Figure 4 . GHB showed a mixed sedative-stimulant pattern mediating both types of effects. GHB produced slight stimulant-like effects as measured by VAS ''stimulated'' that peaked at 45 minutes after drug administration and objective sedation effects as reflected in VAS ''drowsiness.'' The latter peaked between 1 and 1.5 hours after drug administration and lasted for 2 hours.
DISCUSSION
The results of the study provide new insights on GHB pharmacokinetics in nonconventional matrices in humans. . Oral fluid to plasma concentration ratio (oral fluid to plasma ratio) after administration of an oral dose of 50 mg/kg sodium gamma-hydroxybutyric acid in five subjects (mean 6 standard deviation). *Baseline ratio was only estimated by isotopic dilution because basal concentrations of gammahydroxybutyric acid in both matrices were quite low.
GHB given by the oral route is rapidly absorbed and eliminated. Drug consumption can be differentiated from GHB endogenous concentrations both in plasma and urine in a time window of 6 hours after ingestion. Our results are in agreement with those obtained in healthy subjects administered with 4.5 g of oxybate (equivalent to 50-60 mg/kg of GHB) 3 and in terms of C max value, barely double those observed after the administration of a single dose of 25 mg/kg of GHB. 27 In contrast, present results are lower than those observed in severe acute intoxications. 32 GHB was found in oral fluid at peak value concentrations equivalent to one third to one fourth of those found in plasma with an even quicker return to baseline values than that observed in plasma. Therefore, oral fluid and plasma kinetics are poorly related. In early experiments, 27 in which a single oral dose of 25 mg/kg was given, a t max at 15 minutes in oral fluid was reported. Oral fluid samples were collected at 15 minutes, but despite using a drinking device, the authors themselves did not exclude a possible contamination, because GHB concentrations exceeded more than five times those observed in plasma. Taking into account this previous report, in the present study, oral fluid sample collection was started at 0.5 hour after a mouthwash and concentrations observed are closer to those expected following Henderson-Hasselbach modified equation for weak acidic substances (estimated pKa of GHB is approximately 5) excreted into a matrix (oral fluid) more acidic than plasma. 33 Indeed, the saliva plasma ratio was always lower than 1, which indicates that GHB, an acidic drug, did not diffuse to a large extent into oral fluid in contrast with basic drugs such as MDMA, which appears in saliva in concentrations remarkably higher than those in plasma. 33 Furthermore, differently from MDMA and other basic drugs, a large intersubject variability in S/P ratio was found, which prevents any possible correlation of dose-oral fluid concentration. Because GHB oral fluid concentrations are lower than those observed in plasma, they quickly reach baseline concentrations at 3 hours after ingestion, limiting somewhat the time window for detecting its consumption in this biologic matrix and its usefulness in GHB forensic toxicology.
GHB urinary excretion was in accordance with previous reports. 3, 27, 34 In line with early reports, less than 2% of doses administered were recovered in the collection period. Highest recoveries were found in the 0-to 3-hour urine samples.
Concerning GHB detection in sweat, it appears that drug diffusion in this matrix has even more limitations than those found for oral fluid. After drug intake, GHB concentrations both in cotton wipes (which represent a punctual measure of excretion) and in sweat patches (which represent an accumulative measure of excretion) are marginally higher than baseline values when peak concentrations are achieved in plasma. In addition, taking into account the variability in basal concentrations, concentrations of GHB in sweat higher than reported basal values cannot be attributed to its consumption. Therefore, similar to oral fluid, sweat does not appear to be a suitable biologic matrix for monitoring GHB consumption.
GHB was stable during storage conditions and no biotransformation toward GHB formation was observed in the collected matrices.
GHB showed a mixed stimulant-sedative pattern with a biphasic time profile as described for other sedatives (alcohol or cannabis). 35, 36 Psychostimulant effects were predominant in the first hour, whereas sedative effects initiate more slowly and predominate in the second hour after drug administration. GHB plasma and oral fluid concentrations correlated better with psychostimulant-like effects rather than with sedative ones.
CONCLUSION
In summary, the time course of GHB concentrations in oral fluid was similar to that seen in plasma; nevertheless, concentrations were more than three times lower in oral fluid. Oral fluid and sweat appear not to be suitable biologic matrices for monitoring GHB consumption. Some GHB-mediated subjective effects are related to plasma concentrations.
